Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Simulations Plus Inc SLP

Healthcare Medical Devices
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus... see more

Recent & Breaking News (NDAQ:SLP)

Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results

Business Wire October 25, 2023

Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call

Business Wire October 11, 2023

Simulations Plus Receives New FDA Grant Award

Business Wire September 21, 2023

Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors

Business Wire September 7, 2023

Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)

Business Wire August 24, 2023

Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment

Business Wire August 15, 2023

Simulations Plus Releases ADMET Predictor® 11

Business Wire July 13, 2023

Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results

Business Wire July 6, 2023

Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date

Business Wire June 21, 2023

Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities

Business Wire June 20, 2023

Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes

Business Wire May 10, 2023

Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses

Business Wire April 18, 2023

Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results

Business Wire April 5, 2023

MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science

Business Wire March 30, 2023

Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology

Business Wire March 28, 2023

Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call

Business Wire March 21, 2023

Simulations Plus to Present at Sidoti March Small-Cap Conference

Business Wire March 16, 2023

Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds

Business Wire March 15, 2023

Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite(TM) in Version 2023R1

Business Wire March 9, 2023

Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference

Business Wire March 7, 2023